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The use of calcineurin inhibitors in solid organ transplantation results in an increased risk of skin cancer. We
examined the effect of these drugs on DNA repair in normal human keratinocytes after ultraviolet B (UVB) irra-
diation. We found that both cyclosporine A (CsA) and ascomycin inhibited removal of cyclobutane pyrimidine
dimers, and that they also inhibited UVB-induced apoptosis. We also observed that UVB induced nuclear local-
ization of the transcription factor nuclear factor of activated T-cells (NFAT), and that this was blocked by CsA and
ascomycin. These data suggest that the increased risk of skin cancer observed in organ-transplant patients may be
as a result of not only systemic immune suppression but also the local inhibition of DNA repair and apoptosis in
skin by calcineurin inhibitors. These ﬁndings may have implications for the use of topical calcineurin inhibitors in
sun-exposed skin and eyes.
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Calcineurin inhibitors such as cyclosporine A (CsA) and the
ascomycin-related drugs tacrolimus and pimecrolimus are
immunosuppressive drugs used systemically in organ trans-
plantation and topically to treat atopic dermatitis and other
dermatological conditions. These drugs bind to immuno-
philin class proteins (cyclophilins in the case of CsA,
and FK Binding Protein (FKBP) in the case of ascomycin-
type drugs) and these drug–immunophilin complexes then
bind to calcineurin and inhibit its phosphatase activity
(reviewed in Reynolds and Al-Daraji, 2002). Inhibition of cal-
cineurin in circulating lymphocytes prevents nuclear local-
ization of the transcription factor nuclear factor of activated
T-cells (NFAT), and blocks expression of important genes,
such as cytokine genes, involved in T cell activation. The re-
sult is profound systemic suppression of the immune system.
The systemic immune suppression produced by these
drugs is followed by a dramatic rise in the incidence of skin
cancer beginning about 4 y after transplantation (reviewed
in Berg and Otley, 2002). These skin cancers are causally
related to sunlight because they arise predominantly on
sun-exposed skin and they contain mutations in the tumor
suppressor gene p53 that are characteristic of those pro-
duced by UV radiation (McGregor et al, 1997). The skin
cancers are also directly related to the drugs because when
drug treatment ceases tumor formation subsides (Otley
et al, 2001). Lymphocytes isolated from CsA-treated trans-
plant patients are deficient in DNA repair synthesis following
UV exposure (Vamvakas et al, 1996; Weinstein et al, 2000;
Herman et al, 2001). Therefore, the systemic inhibition of
lymphocytes is considered to cause both the immune sup-
pression and the skin cancer.
Topical use of calcineurin inhibitors is considered to
avoid these problems because topical administration avoids
systemic exposure, does not produce systemic immune
suppression, and therefore does not have the same risk of
skin cancer. Here, we show that calcineurin inhibitors CsA
and ascomycin inhibit DNA repair of UV damage and reduce
UV-induced apoptosis in human keratinocytes, the target
cell for many skin cancers.
Results
CsA inhibits cyclobutane pyrimidine dimer repair in
normal human epidermal keratinocytes (NHEK) cells
We investigated the effect of the calcineurin inhibitor CsA on
DNA repair in UVB-irradiated NHEK cells, using the dot-blot
method. Cyclobutane pyrimidine dimers (CPD) formed in
DNA immediately after irradiation and then declined in in-
tensity during 24 h incubation because of DNA excision re-
pair (Fig 1, top, row B vs row C). CsA added at 1 mg per mL
to the cell culture media for 1 h (row D) or 24 h (row E) prior
to irradiation reduced CPD repair during the subsequent 24
h. The intensities of the dots were quantified by image
analysis (Fig 1, bottom). Whereas NHEK removed about
66% of the CPD (po0.001), the cells treated before irradi-
ation with CsA for either 1 or 24 h removed no more than
35% of the CPD, significantly less than untreated cells
(p¼0.023, 0.009, respectively). We observed similar find-
ings in HaCaT-immortalized keratinocytes (data not shown).
CsA and ascomycin inhibit DNA repair in HaCaT As-
comycin is a calcineurin inhibitor structurally unrelated to
CsA but that also binds an immunophilin (FKBP12) to
Abbreviations: CPD, cyclobutane pyrimidine dimers; CsA, cyclos-
porine A; NFAT, nuclear factor of activated T-cells; NHEK, normal
human epidermal keratinocytes; PBS, phosphate-buffered saline
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calcineurin. We found that it too inhibited DNA repair in
HaCaT cells measured by dot-blots (Fig 2). In the first set of
experiments (open bars), UVB-irradiated HaCaT cells re-
paired more than 80% of the CPD from their DNA during
24 h, but pre-treatment for 24 h with CsA at either 0.1 mg per
mL or 1.0 mg per mL significantly inhibited this repair
(po0.05 for either). In a second set of experiments (closed
bars), ultraviolet B (UVB)-irradiated HaCaT cells at a pas-
sage number higher than that of the CsA experiment were
less efficient than in the first experiment in repair during the
24 h following irradiation. Nevertheless, ascomycin at either
0.1 or 1.0 mg per mL significantly inhibited repair of CPD
(po0.05 for either), and there was no significant difference
between these two doses. As a technical note, over the
years, we have observed that the growth rate and repair
efficiency of HaCaT cells decline with passage number.
UVB dose–response of repair with CsA at 6 h We inves-
tigated the effect in NHEK cells of UVB dose on CPD repair
in the presence of calcineurin inhibitors. In this experiment
the results of the dot-blot assay were converted to CPD per
106 DNA bases using l-DNA with a known number of CPD/
106 bases as calibration standards. In Fig 3, we compared
the frequency of CPD remaining in DNA at 6 h post-UVB in
untreated cells with those pre-treated for either 24 or 48 h
with 1 mg per mL of CsA. After a UVB dose of 250 J per m2
UVB, CPD remained in the DNA at 6 h, and there was no
difference among cells with or without CsA. After 500 J per
m2, the cells treated with CsA showed slightly more CPD/
106 base, but with 750 J per m2 there was a clear and
significant difference after only 6 h between cells untreated
and pre-treated with CsA (po0.05). Pre-treatment for 48 h
with CsA produced only a small difference from pre-treat-
ment for 24 h. The difference between CsA treated and
untreated cells remained between 15 and 30 CPD/106
bases after 24 h (data not shown). Assuming an excess of
15 CPD/106 bases and a human genome of 2  109 bases,
the effect of the calcineurin inhibition was to allow about
30,000 of these pre-mutagenic lesions to persist in each
irradiated cell.
Cell survival and apoptosis after UVB and CsA We ex-
pected that the persistence of DNA damage would reduce
Figure 1
Cyclosporine A (CsA) inhibits repair of cyclobutane pyrimidine
dimers (CPD) in ultraviolet B (UVB)-irradiated normal human ep-
idermal keratinocytes. Cellular DNA from four replicates was blotted
and probed with CPD antibodies. UVB was 500 J per m2 and CsA was
at 1 mg per mL. Treatments were: Top: (A) Untreated and unirradiated;
(B) UVB and no incubation; (C) UVB and 24 h incubation; (D) 1 h CsA
pre-treatment, UVB, 24 h incubation; and (E) 24 h CsA pre-treatment,
UVB, 24 h incubation. Bottom: Plot of mean  SEM CPD, normalized
to UVB and no incubation set as 100% (po0.05).
Figure 2
Cyclosporine A (CsA) and ascomycin (Asc) inhibit repair of cyclo-
butane pyrimidine dimers (CPD) in ultraviolet B (UVB)-irradiated
HaCaT cells. Cells were pre-treated for 24 h with either CsA or as-
comycin at the indicated dose and irradiated with 500 J per m2 UVB,
and then incubated for 24 h. DNA was blotted, probed with CPD an-
tibodies, and the CPD intensity was normalized to irradiated cells with
no pre-treatment or incubation. The plot shows the mean  SEM for
CsA treatment (open bars, four replicates) and Asc (closed bars, 16
replicates except 0.1 mg per mL, which was eight replicates; po0.05).
Figure3
Ultraviolet B (UVB) dose–response of cyclosporine A (CsA) inhibi-
tion of repair of cyclobutane pyrimidine dimers (CPD). Normal
human epidermal keratinocytes were untreated (open squares), pre-
treated for 24 h (closed squares) or 48 h (closed circles) with 1 mg per
mL CsA, irradiated with the indicated dose of UVB, and incubated for
6 h. DNA was blotted, probed with CPD antibodies, and the CPD
intensity was converted to CPD/106 bases using UV-l–DNA standards.
The plot is the mean  SEM for three replicates for each data point.
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survival of calcineurin-inhibited cells. On the contrary, we
found that the survival of NHEK cells treated with 1 mg per
mL CsA cells was similar to untreated cells at 250 J per m2
UVB, and at 500 J per m2 UVB the pre-treated cells showed
at least a 40-fold increased colony-forming ability that
was statistically significant (Table I). Similar results were
observed for HaCaT cells (Table I) and JURKAT cells, an
immortalized T cell line (data not shown). Pre-treatment of
HaCaT cells with 1 mg per mL ascomycin also increased
colony-forming ability after 500 J per m2 of UVB by more
than 300-fold compared with untreated cells (p¼0.006,
Table I).
The drug-induced increase in colony-forming ability after
UVB suggested that apoptosis was inhibited. Apoptosis in
UVB-irradiated NHEK cells was measured by the induction
of caspase-3 activity per 105 cells at 24 h after UVB (Fig 4).
Low levels of caspase-3 activity were found in untreated
cells and UVB doses of up to 250 J per m2 produced little
change (data not shown), but 500 J per m2 UVB increased
caspase-3 activity 2- to 8-fold after 24 h (Fig 4). Pre-treat-
ment for 24 h with either CsA or Ascomycin at 1 mg per mL
significantly reduced UVB-induced caspase-3 (Fig 4). We
found variability from experiment to experiment in the
amount of caspase-3 at baseline and after UVB, and this
made combining data from different experiments problem-
atic. In Fig 4, we present one experiment for CsA and one
for ascomycin, and we observed similar results in a total of
six experiments. Taken together, the results suggest that
these calcineurin inhibitors reduced UVB-induced apopto-
sis relative to controls even in the face of increased
persistent DNA damage.
CsA and ascomycin inhibit UV-induced nuclear trans-
location of NFAT The best-understood mode of action for
calcineurin inhibitors is blocking the nuclear localization of
NFAT, a transcription factor for genes activated in T cells.
Huang et al (2000) reported that very high doses of UVB
(4000 J per m2) induced activation of NFAT in mouse ep-
idermal cells and skin, and this was blocked by high doses
of CsA (12 mg per mL). We found that NFAT was mobilized to
the nucleus of NHEK cells at doses between 100 and 500 J
per m2 UVB (Fig 5A) in a concentration-dependent manner.
The localization began within 5 min after 500 J per m2 UVB
and increased up to 4 h (Fig 5B). We found that localization
declined by 24 h (data not shown), whereas Huang et al
(2000) reported that the maximum level of activation in
mouse cells was 18–24 h after UVB. NFAT localization to the
nucleus is dependent on calcium mobilization (Huang et al
2000), and we found that in NHEK cells, CsA and ascomycin
at 1 mg per mL reduced nuclear localization following UVB
Table I. Colony-forming ability of UVB-irradiated NHEK and HaCaT cells
Cell UVB (J/m2)
Colonies per plate  SEM Ratio
p valueCsA þCsA þCsA/CsA
NHEK 0 516  14 561  19 1.1 NS
250 99  16 103  13 1.0 NS
500 0 12  1 440.0 0.002
HaCaT 0 61  4 100  3 1.6 o0.001
250 18  3 8  1 0.4 0.008
500 1  0 15  2 15.0 0.008
Cell UVB (J/m2)
Colonies per plate  SEM Ratio
p valueAsc þAsc þAsc/Asc
HaCaT 0 566  22 716  6 1.3 0.003
125 330  45 326  73 1.0 NS
250 80  4 132  9 1.7 0.006
500 0 104  8 4315 0.006
UVB, ultraviolet B; NHEK, normal human epidermal keratinocytes; CsA, cyclosporine A; Asc, ascomycin.
The number of colonies formed (average of three replicates) by UVB-irradiated cells pre-treated with 1 mg/mL CsA or ascomycin for 24 h compared
with untreated cells.
NS, not significant. Two-tailed t test except differences from zero by the one-sample t test.
Figure 4
Cyclosporine A (CsA) and ascomycin (Asc) inhibit ultraviolet B
(UVB)-induced caspase-3 activation in normal human epidermal
keratinocytes (NHEK). NHEK were pre-treated as indicated with 1 mg
per mL CsA or ascomycin, irradiated with 500 J per m2 UVB, incubated
for 24 h, and caspase-3 activity measured. The plot shows a mean of
two replicates.
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(Fig 5B). Examples of NHEK cells stained for NFAT are
shown below the graphs in Fig 5. The nuclear localization
after 5 min or 4 h is apparent relative to unirradiated cells,
whereas CsA- or ascomycin-treated cells fail to show this
intensity of nuclear fluorescence.
Discussion
Systemic calcineurin inhibitors have had great success in
improving organ transplantation, but they have the unde-
sirable side effect of increasing the risk of cancer in sun-
exposed skin. Topical calcineurin inhibitors have also been
successful for diseases such as atopic dermatitis because
their steroid-sparring effect minimizes dermal atrophy, stri-
ae, and telangiectasia, and they were considered as pre-
venting the skin cancer risk. But, evidence is accumulating
that systemic immune suppression is not the only cause of
the increased risk of skin cancer (Andre´ et al, 2004), and at
least in the case of renal transplant patients, their DNA
repair capacity is impaired (Vamvakas et al, 1996; Herman
et al, 2001).
We report here that the calcineurin inhibitors CsA and
ascomycin each inhibited repair of UV-induced DNA dam-
age in human keratinocytes, the target cell for most skin
cancers. The inhibition is achieved with as low as 0.1 mg per
mL drug, and as quickly as within 1 h after exposure,
whereas the preferred experimental conditions are 1 mg per
mL and 24 h pre-incubation. The concentration of CsA in
the epidermis of a patient treated for psoriasis for 3 d is 2.8
mg per mL (Fisher et al, 1988), and the ascomycin-related
drug tacrolimus is topically applied at 1000 mg per mL (0.1%
wt/vol), whereas pimecrolimus is topically applied at 10,000
mg per mL (1% wt/vol). The magnitude of the effect of CsA
and ascomycin on repair of CPD are dependent on the dose
of UVB, but is observed with a dose of 500 J per m2 UVB
producing less than 100 CPD/106 DNA bases, which is well
with the range of minimal erythemal doses for skin types I–III
(Ho¨nigsmann et al, 1987; Hemminki et al, 2002).
We suspect that the cause of the reduced DNA repair is
because of inhibition of calcineurin, as two drugs with dif-
ferent structures and different methods of calcineurin inhi-
bition both inhibited DNA repair. CsA inhibits calcineurin by
binding it with cyclophilin A, whereas ascomycin inhibits it
by binding it with FKBP12. We further speculate that tran-
scription factor NFAT participates in DNA repair, and that
the inhibition of calcineurin prevents dephosphorylation of
NFAT1 and its nuclear localization. Consistent with this
hypothesis, UVB induces nuclear localization of NFAT1, as
part of a ‘‘UV response’’ (Fig 5, Huang et al, 2000). Tran-
scription factors are the first proteins to encounter DNA
damage during transcription, and several have been iden-
tified in DNA repair complexes (Svejstrup, 2003).
The persistence of DNA damage is itself a risk factor for
skin cancer. Diminished DNA repair capacity causes an in-
creased risk for skin cancer (Wei et al, 1993), and poly-
morphisms in DNA repair genes that may reduce DNA repair
are correlated with cancer risk, including skin cancer
(Goode et al, 2002). In the extreme case of the disease
xeroderma pigmentosum, genetic mutations inactivate DNA
repair genes and increase the skin cancer risk by 1000-fold
(Kraemer et al, 1987).
These calcineurin inhibitors also inhibited UV-induced
apoptosis in addition to DNA repair. CsA has previously
been reported to inhibit apoptosis by two mechanisms:
(1) by binding of cyclophilin A to calcineurin, it blocks
Figure 5
Nuclear localization of nuclear factor of activated T-cells (NFAT) after ultraviolet B (UVB) is inhibited by cyclosporine A (CsA) and ascomycin
(Asc). (A) Normal human epidermal keratinocytes (NHEK) were UVB irradiated with the indicated dose. After 4 h, the amount of NFAT localized in the
nucleus was determined by immunofluorescence, and normalized to the amount at the maximum dose. (B) NHEK were pre-incubated for 24 h with 1
mg per mL of either CsA or ascomycin, UVB irradiated, and incubated for either 5 min or 4 h before staining for nuclear NFAT. The plots show
means  SEM from at least 80 cells. Bottom: images of cells as labeled from the panel B experiment. Note: images of cells with little nuclear
fluorescence are dark with very light and diffuse staining.
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dephosphorylation of the apoptosis-inducer Bcl 2-antago-
nist of cell death (BAD), and (2) by binding of cyclophilin D to
mitochondrial permeability transition pore protein, it pre-
vents release of the apoptosis-inducer cytochrome C
(Waldmeier et al, 2002). As ascomycin also reduces ca-
spase-3 induction (Fig 4) but does not bind cyclophilin D,
we suspect that the first mechanism, blocking BAD de-
phosphorylation, is important in keratinocytes as it is in
other cells (Yang et al, 2004).
Inhibition of apoptosis is recognized as a tumor-promot-
ing event in skin cancer (Bernstein et al, 2002, Guzman et al,
2003). For example, mutational inactivation of the p53 DNA
repair gene leads to a reduction of ‘‘sunburn cells’’ or apo-
ptotic keratinocytes, and this is an early event in skin cancer
(Ziegler et al, 1994). The combination of persistent DNA
damage in cells and the inhibition of apoptotic removal of
such cells, both caused by calcineurin inhibitors, creates a
potential for increased risk of skin cancer.
This combination of reduced DNA repair and reduced
apoptosis leading to skin cancer has been observed in
mice, whether the calcineurin inhibitor is administered sys-
temically or topically. Systemic administration of CsA in
mice reduced DNA repair synthesis in the epidermis fol-
lowing UVB exposure, and also suppressed the appearance
of apoptotic sunburn cells (Sugie et al, 2002). It was dis-
closed at the time of approval of both tacrolimus and pi-
mecrolimus that topical treatment of mice with the drugs
during exposure to solar-simulating light shortened the
mean time to skin tumor formation,1,2 but both studies were
flawed by the greatly increased photocarcinogenesis pro-
duced by the vehicle alone. Topical treatment of mice with
tacrolimus dramatically increased the induction of skin
tumors after exposure to the carcinogen 7,12-dimethyl bene
a anthracene (DMBA) (Niwa et al, 2003).
The published long-term safety studies in humans of
topical calcineurin inhibitors have not been designed to de-
tect an increased risk of skin cancer. They have been of only
1 y duration and were underpowered to measure significant
changes in skin cancer rates (Kang et al, 2001; Luger et al,
2004). As a point of reference, organ transplantation
became widespread in 1965, and the first report of an
association with skin cancer appeared from Australia 7 y
later (Marshall 1972).
Topical calcineurin inhibitors are approved for use in
adults and in children as young as 2 y old. Of special note is
their use in vitiligo, in which the drug may precede, follow, or
be combined with UVB to stimulate pigmentation (Passeron
et al, 2004; Silverberg et al, 2004). An additional indication is
the approved use of 0.05% (500 mg per mL) CsA eyedrops
for treatment of dry eye. UVB damages the corneal epithe-
lium and endothelium, and DNA repair is an important
part of the cellular defense (Brenner and Grabner, 1981).
Xeroderma pigmentosum patients are deficient in DNA
repair and their rate of neoplasms of the anterior eye,
including corneal epithelioma, is elevated about 2000-fold
for patients 20 y and younger (Kraemer et al, 1987).
They also suffer from corneal clouding and vascularization
at an early age.
In summary, the data presented here suggest that the
increased rates of skin cancer observed in organ transplant
patients may be as a result of not only systemic immune
suppression of circulating T cells but also the inhibition of
DNA repair and apoptosis in skin by calcineurin inhibitors.
These findings may have implications for the use of topical
calcineurin inhibitors in sun-exposed skin and eyes. The
FDA has recently issued alerts concerning topical calcine-
urin inhibitors.3,4
Materials and Methods
NHEK were purchased from Cascade Biologics (Portland, OR) and
cultured in their Epilife medium containing the human keratinocyte
growth supplement kit. Each experiment was performed with cells
from a single donor. HaCaT cells were cultured in the Invitrogen
(Carlsbad, CA) Dulbeccos minimal essential medium low-glucose
medium with 1% pen/strep, 1% L-glutamine, 1% non-essential
amino acids, and with 10% heat-inactivated fetal bovine serum
(Sigma, St Louis, MO). All cells were incubated in a 371C incubator
with a 5% humidified CO2 atmosphere.
CsA was pharmaceutical grade (identity and purity confirmed
by infrared and high-performance liquid chromatography), but
equivalent research grade is available from Sigma, St Louis, MO.
Ascomycin was from Alexis, San Diego, CA. The drugs were di-
luted in ethanol, added to the media, and incubated for 1–48 h
prior to irradiation. The media were collected and replaced with
phosphate-buffered saline (PBS). The cells were irradiated with
two FS40 UVB bulbs (Phillips, Twinsburg, OH) filtered with Kodacel
paper (Kodak, Rochester, New York) that absorb UVC. Sixty-five
percent of the UVB energy was in the 290–320 nm range with a
peak emission at 313 nm. The UVB radiation was measured using
a Model IL1400A Radiometer/Photometer and a UVB#21303/
W#9560 probe (International Light Inc., Newburyport, MA). After
irradiation, the PBS was replaced with fresh media or the media
containing CsA or ascomycin.
CPD were measured in UV-irradiated DNA by the Southwestern
dot-blot method using antibodies against CPD (Yarosh et al, 2002),
with the exception that the filters were not baked. Dot blots were
loaded with equal OD260 units of DNA extracted from cells, and
loading was measured by staining equally loaded neutral agarose
gels with ethidium bromide. Dots were visualized using a Kodak
IS440CF imaging station (Kodak, Rochester, NY) and quantified by
image analysis TotalLab (Phoretix Intl., Durham, NC) and normal-
ized for loading. The blots in Fig 3 were calibrated using standards
of l-DNA irradiated with a range of UV doses. The number of
CPD per 106 bases in these standards was determined by the
alkaline agarose gel method using l-HindIII fragments for calibra-
tion (Yarosh et al, 2002). The blots were developed by phospho-
fluorescence, and the intensity of the images was analyzed
by TotalLab.
For colony formation, cells were plated into Corning (Corning,
Corning, NY) T-75 flasks, and after drug treatment, cells were
counted using a Coulter Z1 Particle Counter (Beckman Coulter,
Hialeah, FL). One thousand cells were plated into 100 mm cell
culture dishes (Corning) and after incubation for 5–6 h the plates in
triplicate were irradiated with UVB and fresh media with drug were
again added. The cells were incubated for 7 d at 371, fixed
with methanol, stained with 0.25% methylene blue in PBS, and the
colonies were counted.
Caspase-3 was measured using a Rediplate96 EnzCheck-
Caspase-3 Assay Kit (Molecular Probes, Eugene, OR). Briefly,
1Dermatologic and Ophthalmic Drugs Advisory Committee, US
FDA. Meeting No. 54. November 16, 2000, at http://www.fda.gov/
ohrms/dockets/ac/00/slides/3659s1_02_fitzsimmons/sld006.htm.
2Approval Package, Elidel (Pimecrolimus) Cream; Application
No. 21-302, Approval Date: 12/13/01, at www.fda.gov/cder/foi/
nda/2001/21-302_Elidel.htm.
3www.fda.gov/cder/drug/infosheets/hcp/protopichcp.htm
4www.fda.gov/cder/drug/infosheets/hcp/elidelhcp.htm
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cell lysate was mixed with the kit substrate and the fluorescence
excitation/emission at 496/520 nm was measured on a Spectra-
Max Gemini XPS fluorescent plate reader (Molecular Devices,
Eugene, OR).
For NFAT immunofluorescence microscopy, cells were fixed
on the slides with a 3:1 solution of methanol:acetic acid for 10 min,
washed with PBS, then PBS/0.1% Triton X-100, and then blocked
with 5% powdered milk in PBS. The anti-NFAT1 antibody (Upstate
Biotech, Lake Placid, NY) was incubated with the slides overnight
at 41C. The slides were developed with a fluorescein isothiocyan-
ate-conjugated secondary antibody (Santa Cruz Biotechnology,
Santa Cruz, CA), mounted with SlowFADE (Molecular Probes), and
digitally photographed using an Olympus BX51 fluorescence mi-
croscope (Olympus, Melville, New York) at  400 magnification.
The total fluorescence of each isolated nucleus in the digital pic-
tures was analyzed using TotalLab, and 80 or more cells were
analyzed per sample.
Statistical analysis was carried out by the Student’s or Welch’s t
test unless otherwise noted, using the computer program InStat
(GraphPad Software Inc., San Diego, CA).
DOI: 10.1111/j.0022-202X.2005.23858.x
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